ABRYSVO™: Pfizer Canada’s Newly Publicly Funded Vaccine a Step Towards National RSV Prevention in Older Adults
Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults in Canada for 2024-2025. ABRYSVO™ is approved by Health Canada for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age and older.iABRYSVO™is also […]